ChAdOx1-MVA 5T4 vaccine
ADVANCE
Phase 2 mab terminated
Quick answer
ChAdOx1-MVA 5T4 vaccine for Intermediate Risk Prostate Cancer is a Phase 2 program (mab) at Barinthus Biotherapeutics plc. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Barinthus Biotherapeutics plc.
- Indication
- Intermediate Risk Prostate Cancer
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated